Kiora Pharmaceuticals licenses KIO-301 South Korea rights to CKD for $1 million upfront
Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation (CKD) an exclusive license to develop and commercialize KIO-301 in South Korea for retinitis pigmentosa and other ophthalmology uses, under an agreement effective August 20, 2026. Kiora will receive a $1.0 million upfront payment, plus eligible milestone payments and double-digit royalties on South Korean net sales, and says the deal completes its global partner network for the product.
Key points
- CKD pays a $1.0 million upfront payment to Kiora under the Exclusive License and Development Agreement.
- Kiora is eligible for clinical, regulatory and sales milestone payments and double-digit royalties on net sales of KIO-301 in South Korea.
- CKD will handle development and commercialization in South Korea; Kiora expects its partners Laboratoires Théa, Senju Pharmaceutical and CKD to run a single global Phase 3 trial.
- The agreement was announced in a press release dated August 19, 2026, and either party may terminate it upon certain customary events.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.